<?xml version="1.0" encoding="UTF-8"?>
<p id="par0200">The host innate interferon response is crucial for the control of viral replication after infection 
 <xref rid="bib0635" ref-type="bibr">[127]</xref>. Although CoVs can suppress the interferon response for immune evasion, they remain susceptible to interferon treatment 
 <italic>in vitro</italic>
 <xref rid="bib0640" ref-type="bibr">128</xref>, 
 <xref rid="bib0645" ref-type="bibr">129</xref>. The interferon response can be augmented by the administration of recombinant interferons or interferon inducers. Recombinant interferon- α and interferon- β inhibit the replication of both SARS-CoV and MERS-CoV 
 <italic>in vitro</italic> and animal models 
 <xref rid="bib0420" ref-type="bibr">84</xref>, 
 <xref rid="bib0650" ref-type="bibr">130</xref>, 
 <xref rid="bib0655" ref-type="bibr">131</xref>, 
 <xref rid="bib0660" ref-type="bibr">132</xref>, 
 <xref rid="bib0665" ref-type="bibr">133</xref>, 
 <xref rid="bib0670" ref-type="bibr">134</xref>, 
 <xref rid="bib0675" ref-type="bibr">135</xref>. Various combinations of interferon- α or-β with other antivirals such as ribavirin and/or lopinavir-ritonavir have been used to treat patients with SARS or MERS. Overall, combination treatments consisting of interferons and ribavirin did not consistently improve outcomes 
 <xref rid="bib0235" ref-type="bibr">47</xref>, 
 <xref rid="bib0240" ref-type="bibr">48</xref>, 
 <xref rid="bib0245" ref-type="bibr">49</xref>, 
 <xref rid="bib0680" ref-type="bibr">136</xref>, 
 <xref rid="bib0685" ref-type="bibr">137</xref>. The apparent discrepancy between 
 <italic>in vitro</italic> findings and 
 <italic>in vivo</italic> outcomes may be related to the high EC
 <sub>50</sub>/Cmax ratios of these drugs and the delay between symptom onset and drug administration 
 <xref rid="bib0415" ref-type="bibr">83</xref>, 
 <xref rid="bib0690" ref-type="bibr">138</xref>.
</p>
